Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.

NCT01682512 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01682512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01682512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Terminated
Start date
September 5, 2012
Completion date
October 12, 2016
Enrollment
294 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid